ProCE Banner Activity

CE

Improving Safety, Efficiencies, and Reducing Waste with Ready-To-Administer IV Medication: A Roadmap to Success

Video

Many organizations have stated that to avoid the unnecessary, error-prone complexity of IV push medication preparation and administration, and to avoid the risk of contamination and personnel exposure, organizations should  re-evaluate current products administered by IV push and standardize as much as possible to ready-to-administer (RTA) formulations and concentrations.

This webinar will describe reported key safety vulnerabilities associated with IV push medication dose manipulation and challenges with waste management that have led to errors and patient harm. The faculty will explain the benefits of analyzing the cost and time inefficiencies associated with wasting opioids, along with the secondary benefit of reducing diversion opportunities. Methods for optimizing ADC storage in anticipation of adoption of manufacturer-prepared prefilled ready-to-administer (RTA) products will be shared. Lastly, this webinar will provide practitioners insight into the necessary decision making and implementation steps required when transitioning to a manufacturer-prepared prefilled RTA syringe product including the standardization of opioid dosing, and the beneficial impact on safety and nursing workflow. 

Pharmacy Technicians: maximum of 1.00 contact hours

Pharmacists: maximum of 1.00 contact hours

Released: March 01, 2024

Expiration: March 01, 2026

Share

Faculty

Matthew Grissinger, RPh, FISMP

Matthew Grissinger, RPh, FISMP

Director, Education; Institute for Safe Medication Practices

Satya Krishna Ramachandran, MD

Satya Krishna Ramachandran, MD

Associate Professor, Anaesthesia, Harvard Medical School
Vice Chair of Quality, Safety, and Innovation
Beth Israel Deaconess Medical Center
Boston, MA

Michele Sheaffer, RPh

Michele Sheaffer, RPh

Associate Director of Pharmacy Operations
Abington Hospital Jefferson Health
Abington, PA

Acknowledgement

Supported by an independent educational grant from Fresenius Kabi

Provider Statement

Jointly provided by Partners for Advancing Clinical Education (PACE) and ISMP

Target Audience

Medication Safety and Patient Safety Officers, Risk Management and Quality Managers, Medication Safety Committees, Nurses, Pharmacists, Pharmacy Technicians, Physicians

Learning Objectives

Following completion of this activity, participants will be able to:

  • Review the safety challenges and diversion risks associated with the preparation and administration of IV push medications doses that require product manipulation

  • Outline the steps taken and data used to optimize automated dispensing cabinet (ADC) storage capacity in anticipation of the transition to RTA syringes

  • Describe one organization’s successful journey towards medication safety, waste reduction, and workflow efficiencies, when adopting RTA syringes

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

    • Matthew Grissinger, RPh, FISMP, activity director for this activity, has no relevant financial relationships.
    • Satya Krishna Ramachandran, MD, faculty for this activity, consultant/advisor/speaker for Fresenius Kabi.
    • Michele Sheaffer, RPh, faculty for this activity, consultant/advisor/speaker for Fresenius Kabi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Miller Medical Communications. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Pharmacist Continuing Education
PACE designates this continuing education activity for 1 contact hour(s) (0.10 CEUS) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-24-036-H05-P/T
Type of Activity: Knowledge

Nurses
This activity has been approved for up to 1.0 California State Nursing contact hours by the provider, Debora Simmons, who is approved by the California Board of Registered Nursing, Provider Number CEP 13677. Credit will only be issued to individuals that are individually registered and attend the entire program.

Additional Information

Instructions for Credit

  1. There are no fees for participating in and receiving CE credit for this activity.
  2. During the period February 26, 2024 through February 26, 2026, participants must read the educational objectives and faculty disclosures and study the educational activity.
  3. If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
  4. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
  5. Pharmacists/Technicians: Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Estimated time to complete activity: 1.0 hour